A detailed history of China Universal Asset Management Co., Ltd. transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 11,561 shares of RYTM stock, worth $488,799. This represents 0.06% of its overall portfolio holdings.

Number of Shares
11,561
Previous 11,561 -0.0%
Holding current value
$488,799
Previous $501,000 0.2%
% of portfolio
0.06%
Previous 0.06%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$39.12 - $52.44 $184,802 - $247,726
4,724 Added 69.09%
11,561 $501,000
Q4 2023

May 21, 2024

SELL
$21.39 - $49.64 $101,046 - $234,499
-4,724 Reduced 40.86%
6,837 $314,000
Q4 2023

Jan 23, 2024

BUY
$21.39 - $49.64 $115,056 - $267,013
5,379 Added 368.93%
6,837 $314,000
Q3 2023

May 21, 2024

BUY
$15.81 - $27.8 $11,272 - $19,821
713 Added 95.7%
1,458 $33,000
Q3 2023

Oct 30, 2023

BUY
$15.81 - $27.8 $11,272 - $19,821
713 Added 95.7%
1,458 $33,000
Q2 2023

May 21, 2024

SELL
$16.32 - $21.15 $293 - $380
-18 Reduced 2.36%
745 $12,000
Q2 2023

Jul 27, 2023

SELL
$16.32 - $21.15 $293 - $380
-18 Reduced 2.36%
745 $12,000
Q1 2023

May 21, 2024

BUY
$16.88 - $34.24 $3,224 - $6,539
191 Added 33.39%
763 $13,000
Q1 2023

Apr 27, 2023

BUY
$16.88 - $34.24 $3,224 - $6,539
191 Added 33.39%
763 $14,000
Q4 2022

May 21, 2024

SELL
$22.25 - $30.25 $244,505 - $332,417
-10,989 Reduced 95.05%
572 $16,000
Q4 2022

Jan 31, 2023

BUY
$22.25 - $30.25 $2,158 - $2,934
97 Added 20.42%
572 $17,000
Q3 2022

Oct 21, 2022

BUY
$4.3 - $30.85 $2,042 - $14,653
475 New
475 $12,000

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $2.36B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.